Chopra Vineet, Wesorick David H, Sussman Jeremy B, Greene Todd, Rogers Mary, Froehlich James B, Eagle Kim A, Saint Sanjay
Division of General Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA.
Arch Surg. 2012 Feb;147(2):181-9. doi: 10.1001/archsurg.2011.897.
To assess the influence of perioperative statin treatment on the risk of death, myocardial infarction, atrial fibrillation, and hospital and intensive care unit length of stay in statin-naive patients undergoing cardiac or noncardiac surgery.
MEDLINE via PubMed, EMBASE, Biosis, and the Cochrane Central Register of Controlled Trials via Ovid. Additional studies were identified through hand searches of bibliographies, trial Web sites, and clinical experts. Randomized controlled trials reporting the effect of perioperative statins in statin-naive patients undergoing cardiac and noncardiac surgery were included.
Two investigators independently selected eligible studies from original research published in any language studying the effects of statin use on perioperative outcomes of interest.
Two investigators performed independent article abstraction and quality assessment.
Fifteen randomized controlled studies involving 2292 patients met the eligibility criteria. Random-effects meta-analyses of unadjusted and adjusted data were performed according to the method described by DerSimonian and Laird. Perioperative statin treatment decreased the risk of atrial fibrillation in patients undergoing cardiac surgery (relative risk [RR], 0.56; 95% CI, 0.45 to 0.69; number needed to treat [NNT], 6). In cardiac and noncardiac surgery, perioperative statin treatment reduced the risk of myocardial infarction (RR, 0.53; 95% CI, 0.38 to 0.74; NNT, 23) but not the risk of death (RR, 0.62; 95% CI, 0.34 to 1.14). Statin treatment reduced mean length of hospital stay (standardized mean difference, -0.32; 95% CI, -0.53 to -0.11) but had no effect on length of intensive care unit stay (standardized mean difference, -0.08; 95% CI, -0.25 to 0.10).
Perioperative statin treatment in statin-naive patients reduces atrial fibrillation, myocardial infarction, and duration of hospital stay. Wider use of statins to improve cardiac outcomes in patients undergoing high-risk procedures seems warranted.
评估围手术期他汀类药物治疗对初次接受他汀类药物治疗的心脏或非心脏手术患者的死亡、心肌梗死、心房颤动风险以及住院时间和重症监护病房住院时间的影响。
通过PubMed检索MEDLINE、通过Ovid检索EMBASE、Biosis以及Cochrane对照试验中央注册库。通过手工检索参考文献、试验网站和临床专家确定了其他研究。纳入了报告围手术期他汀类药物对初次接受他汀类药物治疗的心脏和非心脏手术患者影响的随机对照试验。
两名研究人员独立从以任何语言发表的原始研究中选择符合条件的研究,这些研究探讨了他汀类药物使用对感兴趣的围手术期结局的影响。
两名研究人员进行了独立的文章摘要和质量评估。
15项涉及2292例患者的随机对照研究符合纳入标准。根据DerSimonian和Laird描述的方法对未调整和调整后的数据进行随机效应荟萃分析。围手术期他汀类药物治疗降低了心脏手术患者发生心房颤动的风险(相对风险[RR],0.56;95%置信区间[CI],0.45至0.6***;需治疗人数[NNT],6)。在心脏和非心脏手术中,围手术期他汀类药物治疗降低了心肌梗死的风险(RR,0.53;95%CI,0.38至0.74;NNT,23),但未降低死亡风险(RR,0.62;95%CI,0.34至1.14)。他汀类药物治疗缩短了平均住院时间(标准化平均差,-0.32;95%CI,-0.53至-0.11),但对重症监护病房住院时间没有影响(标准化平均差,-0.08;95%CI,-0.25至0.10)。
初次接受他汀类药物治疗的患者围手术期使用他汀类药物可降低心房颤动、心肌梗死风险并缩短住院时间。在接受高风险手术的患者中更广泛地使用他汀类药物以改善心脏结局似乎是合理的。